<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377854</url>
  </required_header>
  <id_info>
    <org_study_id>H-19055497</org_study_id>
    <nct_id>NCT04377854</nct_id>
  </id_info>
  <brief_title>Prognostic Value of BNP in MCS - a 25 Year Follow up Study</brief_title>
  <official_title>The Prognostic Value of proBNP in Patients Supported With Durable Mechanical Circulatory Assist Devices - a 25 Year Follow up Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A biobank has been created to investigate the prognostic value of biomarkers (mainly BNP) in&#xD;
      patients implanted with durable mechanical assist devices comparing patients with advanced HF&#xD;
      supported by MCS with those who are transplanted and those who remain on optimal medical&#xD;
      therapy.&#xD;
&#xD;
      Patients will be followed up for 25 years after inclusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients referred for advanced HF treatment at the Dept of Cardiology at Rigshospitalet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2045</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2045</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>25 Years</target_duration>
  <primary_outcome>
    <measure>Alive</measure>
    <time_frame>25 years from inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dead</measure>
    <time_frame>25 years from inclusion</time_frame>
    <description>Dead after inclusion in study</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Heart Failure</condition>
  <condition>Left Ventricular Assist Device</condition>
  <condition>Prognosis</condition>
  <condition>Durable Mechanical Support Device</condition>
  <arm_group>
    <arm_group_label>MCS recipients</arm_group_label>
    <description>All recipients of durable MCS will be followed up on a yearly basis with collection of blood sample and clinical data for 25 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recipient of cardiac transplant</arm_group_label>
    <description>All recipients of cardiac transplantation(s) will be followed up on a yearly basis with collection of clinical data for 25 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Watchful waiting at Rigshospitalet</arm_group_label>
    <description>Patients referred for evaluation for treatment with advanced treatment (LVAD/HTX) but -for whatever reason- these pts will be on watchful waiting at the Rigshospitalet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation. No intervention per se.</intervention_name>
    <description>Observation. No intervention (no collection of blood).</description>
    <arm_group_label>Recipient of cardiac transplant</arm_group_label>
    <arm_group_label>Watchful waiting at Rigshospitalet</arm_group_label>
    <other_name>1) Observation - No intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2) Observation and collection and of blood sample</intervention_name>
    <description>All patients evaluated for adv HF (HTX/LVAD) will be offered to contribute to this database; Blood samples will be collected from all at baseline. Patients receiving LVAD will contribute on a yearly basis (or until withdrawal of consent). For other patients no further blood will be collected unless they receive an LVAD at a later point.</description>
    <arm_group_label>MCS recipients</arm_group_label>
    <other_name>Blood sample</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients referred for evaluation for advanced HF treatment at the Rigshospitalet in&#xD;
        Denmark. All patients with Advanced HF (regardless of type of adv HF treatment) at the&#xD;
        contributing center will (hopefully) be included in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients referred for evaluation for advanced HF treatment at the Rigshospital in&#xD;
             Denmark&#xD;
&#xD;
          -  Age&gt;18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Kiran Mirza, MD</last_name>
    <phone>+4535451442</phone>
    <email>KiranMirza@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Finn Gustafsson, MD, PhD, DMSci</last_name>
    <phone>+4535459743</phone>
    <email>Finn.Gustafsson@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>DK</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiran Mirza, MD</last_name>
      <phone>+4535451442</phone>
      <email>kmir0003@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Finn Gustafsson, MD,PhD,DMSc.</last_name>
      <phone>+4535459743</phone>
      <email>Finn.Gustafsson@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 3, 2020</study_first_submitted>
  <study_first_submitted_qc>May 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Finn Gustafsson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

